This paper is for research and educational purposes only. Peritoneal carcinomatosis is an advanced-stage cancer requiring immediate professional oncological care, preferably at a center with CRS+HIPEC expertise. No Christos™ device has regulatory clearance. The Christos™ protocol complements — it does not replace — standard oncological care. All [HY] claims require experimental validation.
Abstract
Peritoneal carcinomatosis — the spread of malignant tumor deposits across the peritoneal lining of the abdominal cavity — represents one of oncology's most challenging presentations. Arising most commonly from colorectal, ovarian, gastric, and appendiceal primary cancers, it is classified as advanced-stage disease and historically carried a poor prognosis with conventional systemic chemotherapy alone.
The emergence of cytoreductive surgery (CRS) combined with hyperthermic intraperitoneal chemotherapy (HIPEC) has transformed outcomes for selected patients. For patients with high-burden disease or primaries less responsive to HIPEC, significant challenges remain. This paper presents the Christos™ coherence medicine protocol — a five-pillar framework designed to function as an adjunct to CRS+HIPEC, as primary support where surgery is not feasible, and as a maintenance protocol following surgical remission.
Part I: The Conventional Framework
Understanding peritoneal carcinomatosis, the PCI scoring system, and the CRS+HIPEC standard of care
Understanding Peritoneal Carcinomatosis
What It Is [EP]
The peritoneum is a thin mesothelial membrane lining the abdominal cavity and the outer surfaces of most abdominal organs. Peritoneal carcinomatosis occurs when cancer cells — having escaped their primary organ of origin — implant and grow as discrete tumor deposits across this peritoneal surface. This is not the formation of a single new tumor. It is the simultaneous seeding of the entire peritoneal surface with potentially hundreds of microscopic to macroscopic tumor nodules.
| Primary Cancer | Frequency of PC | HIPEC Eligibility |
|---|---|---|
| Colorectal cancer | 15–20% of patients | Yes — established indication |
| Ovarian cancer | 60–70% of advanced cases | Yes — standard of care in advanced disease |
| Appendiceal cancer (pseudomyxoma) | Essentially 100% of PMP | Yes — strongest evidence base |
| Gastric cancer | 15–30% of advanced cases | Selected cases — evidence evolving |
| Peritoneal mesothelioma | Primary peritoneal disease | Yes — established indication |
The Peritoneal Cancer Index (PCI) [EP]
The PCI divides the abdomen and pelvis into 13 anatomical regions, scoring each from 0 (no tumor) to 3 (large or confluent disease). Maximum score: 39. PCI is the single most important predictor of surgical outcome:
| PCI Score | Disease Burden | Surgical Eligibility | Expected Outcome |
|---|---|---|---|
| <10 | Low | Strong candidate for CRS+HIPEC | Best outcomes; potential long-term remission |
| 10–20 | Moderate | Candidate in experienced hands | Good outcomes in specialized centers |
| 21–30 | High | Selected cases only | Challenging; highly variable |
| >30 | Very high / diffuse | Generally not eligible | Systemic therapy primary |
CRS + HIPEC: The Standard of Care [EP]
Cytoreductive surgery (CRS) aims to remove all visible peritoneal tumor deposits. The goal is CC-0 (no visible residual disease) — the strongest predictor of survival. Immediately following CRS, HIPEC perfuses the abdominal cavity with heated chemotherapy solution (41–43°C) for 60–90 minutes, targeting microscopic residual disease. Published outcomes with CRS+HIPEC range from median OS of 30–63 months in colorectal PC to >70% 5-year survival in optimal appendiceal cases.
For patients ineligible for CRS+HIPEC — and for preventing recurrence in those who have undergone it — the Christos™ coherence framework offers its most compelling research agenda.
Part II: The Christos™ Coherence Framework
Five-pillar protocol for peritoneal field restoration — adjunct to CRS+HIPEC, primary support, and maintenance
The Coherence Model of Peritoneal Carcinomatosis [HY]
The Christos™ framework proposes that peritoneal seeding represents the propagation of a coherence failure across a biological field boundary. The peritoneum, in this model, is not merely a passive surface on which seeds land. It is a dynamic field membrane whose coherence integrity determines whether disseminated cancer cells can implant, survive, and proliferate.
This coherence model has one critical therapeutic implication: even after successful CRS+HIPEC removes all visible tumor, if the peritoneal field coherence is not restored, microscopic residual cells will find a biologically permissive environment for reimplantation. Recurrence is not just a failure of surgery. It is a failure to restore field coherence. [HY]
The Five-Pillar Protocol
The primary goal is to restore coherence to the peritoneal field membrane — the biological boundary that, when intact, prevents tumor seeding and propagation:
- PeritoPatch (PP-1) — Christos™ abdominal field resonator worn 24/7 over the full abdomen [ED/HY]
- Abdominal PEMF — pulsed electromagnetic field over abdomen, 30 min twice daily [ED]
- Coherence Lock Practice — 17-second breath hold with focus on the abdomen, 3–5x daily [HY]
- Structured Water — 2–3L daily; warm structured water compress over abdomen 20 min twice daily [HY]
- Vitamin D3 — 10,000 IU daily; regulates T-cell and NK cell function [EP]
- Zinc — 30mg daily; T-cell development; immune function [EP]
- Selenium — 200mcg daily; NK cell function; antioxidant [EP]
- Medicinal Mushrooms (Turkey Tail + Reishi) — 2g daily; beta-glucan immune modulation [EP]
- Omega-3 (DHA/EPA) — 4g daily; reduces PGE2 tumor immunosuppression [EP]
- Probiotics — 100 billion CFU daily; gut microbiome immune support [EP]
- Melatonin — 20mg at night; NK cell activation; anti-tumor activity in vitro [EP]
The PeritoFlux therapeutic fluid is formulated specifically for peritoneal carcinomatosis support — combining evidence-based nutraceuticals for peritoneal tissue integrity and anti-tumor immune function with the Christos™ frequency-imprinting protocol.
Evidence-based oral nutraceutical support (independently available):
- Liposomal Curcumin — 2g twice daily; inhibits NF-kB; anti-angiogenic [EP]
- N-Acetyl Cysteine (NAC) — 600mg daily; glutathione precursor; antioxidant [EP]
- Alpha-Lipoic Acid — 300mg daily; antioxidant; reduces oxidative stress [EP]
- Quercetin — 500mg twice daily; anti-inflammatory; anti-angiogenic [EP]
- Vitamin C (buffered) — 5g daily; antioxidant support [EP]
- Ginger Extract — 500mg 3x daily; anti-nausea; anti-inflammatory [EP]
- Ketogenic Diet — net carbs <50g/day; reduces IGF-1 and insulin; tumor cells cannot use ketones efficiently [EP]
- Intermittent Fasting (16:8) — reduces growth factors; triggers autophagy [EP]
- Pre-HIPEC Fast (48 hours, if applicable) — differential stress sensitization [EP]
- 72-Hour Quarterly Fast — cancer stem cell elimination; immune regeneration [EP]
- Complete elimination of processed sugar and alcohol [EP]
The Christos™ device protocol for peritoneal carcinomatosis includes the PeritoPatch abdominal field resonator, the Frequency Sweep Wand for weekly abdominal sessions, and Coherence Chamber immersive sessions.
The 90-Day Intensive Protocol
Reduce systemic inflammation, establish nutritional coherence support, activate immune system, and begin peritoneal field restoration. Simultaneously pursue conventional care evaluation (PCI assessment, surgical eligibility determination, chemotherapy if indicated).
Escalate anti-tumor pressure through metabolic and immune intensification. Add 72-hour water fast (days 31–34). If CRS+HIPEC was performed, transition into active recovery support. If surgery was not performed, intensify all coherence protocols.
Consolidate gains, support peritoneal tissue regeneration, and transition to sustainable long-term protocol. Establish recurrence-prevention foundation including quarterly 72-hour fasting protocol.
Support During Conventional Treatment
Pre-Surgical Support (4 Weeks Before CRS+HIPEC) [EP/ED]
Patients who enter surgery with better nutritional status, higher immune function, and lower systemic inflammation consistently demonstrate better surgical outcomes and faster recovery. The four weeks before CRS+HIPEC are critical for optimization.
Chemotherapy Side Effect Support [EP]
| Side Effect | Coherence Medicine Support | Classification |
|---|---|---|
| Nausea / vomiting | Ginger extract 500mg 3x daily; abdominal frequency therapy | [EP] |
| Fatigue | CoQ10, PQQ, B-complex mitochondrial support; exercise | [EP] |
| Peripheral neuropathy | Alpha-lipoic acid 600mg; acetyl-L-carnitine 1g; methyl B12 5mg | [EP] |
| Immune suppression | Full immune stack; medicinal mushrooms; probiotics 100B CFU | [EP] |
| Hepatotoxicity | Milk thistle 200mg 3x daily; NAC 600mg daily | [EP] |
What a Patient Can Do Today
The Deeper Truth
Peritoneal carcinomatosis is widely regarded as one of oncology's most challenging presentations. The development of CRS+HIPEC changed this narrative for a meaningful subset of patients. But it did not change it for everyone.
The coherence framework offers a different lens: peritoneal carcinomatosis is not simply the mechanical deposit of tumor seeds on a passive surface. It is a failure of biological field integrity. The peritoneum has lost its capacity to reject incoherent cellular migrants. Restoring that integrity is a research agenda with measurable endpoints — and one that begins today, with the supplement stack and the ketogenic diet, while the device validation work proceeds.
The peritoneum is a field boundary. When its coherence is intact, it rejects what does not belong. Restore the boundary, and the cancer cannot spread. This is the hypothesis. The experiment is what comes next.
References
- Sugarbaker PH. Peritoneal carcinomatosis: a multi-disciplinary problem for the new millennium. World J Surg Oncol. 2005;3:9.
- Verwaal VJ, et al. Randomized trial of cytoreduction and HIPEC versus systemic chemotherapy in peritoneal carcinomatosis of colorectal cancer. J Clin Oncol. 2003;21(20):3737-3743.
- Elias D, et al. Complete cytoreductive surgery plus intraperitoneal chemohyperthermia with oxaliplatin for peritoneal carcinomatosis of colorectal origin. J Clin Oncol. 2009;27(5):681-685.
- Jacquet P, Sugarbaker PH. Clinical research methodologies in diagnosis and staging of patients with peritoneal carcinomatosis. Cancer Treat Res. 1996;82:359-374.
- Aggarwal BB, Harikumar KB. Potential therapeutic effects of curcumin. Int J Biochem Cell Biol. 2009;41(1):40-59.
- Lim YC, et al. Effect of fasting on cancer immunotherapy. J Clin Invest. 2022;132(9):e152283.
- McCraty R, Shaffer F. Heart Rate Variability. Glob Adv Health Med. 2015;4(1):46-61.